Among 4,677 matched pairs of Medicare Advantage beneficiaries (mean age 72) with concurrent heart failure and obesity, adding a GLP-1 receptor agonist to standard heart failure therapy reduced all-cause inpatient utilization by 11% (RR 0.89, 95% CI 0.84–0.93) and avoidable hospitalizations by 12% (RR 0.88, 95% CI 0.82–0.94) over one year. Emergency department visits were statistically unchanged. Medical costs fell 4.7%, though total costs rose 30.6% driven by a 105.9% increase in pharmacy expenditures.
These real-world findings matter enormously given the demographic reality: heart failure with obesity — a phenotype increasingly called HFpEF-obesity — represents one of the fastest-growing cardiovascular burdens in adults over 65. Prior landmark trials like STEP-HFpEF demonstrated semaglutide's symptomatic and functional benefits, but healthcare utilization data in a Medicare population has been sparse. This study fills that gap meaningfully.
However, the cost picture is sobering: avoided hospitalizations do not yet offset GLP-1 drug costs, a critical consideration for payers and policymakers. The observational design introduces residual confounding risks despite propensity matching, and the two-year data window may underestimate longer-term cost offsets as hospitalizations compound. Crucially, this is a preprint not yet peer-reviewed, meaning methodology and conclusions require independent scrutiny before influencing clinical or coverage policy. Still, the convergence of trial and real-world evidence positions GLP-1 agonists as clinically meaningful — if economically complex — additions to heart failure management in older adults with obesity.
